biochanin A, biochanin A, 14C-labeled, genistein 4-methyl ether
Name | Biochanin A | ||
PubChem CID | 5280373 | ||
Molecular Weight | 284.26g/mol | ||
Synonyms |
biochanin A, biochanin A, 14C-labeled, genistein 4-methyl ether |
||
Formula | C₁₆H₁₂O₅ | ||
SMILES | COC1=CC=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)O | ||
InChI | 1S/C16H12O5/c1-20-11-4-2-9(3-5-11)12-8-21-14-7-10(17)6-13(18)15(14)16(12)19/h2-8,17-18H,1H3 | ||
InChIKey | WUADCCWRTIWANL-UHFFFAOYSA-N | ||
CAS Number | 491-80-5 | ||
ChEMBL ID | CHEMBL131921 | ||
ChEBI ID | CHEBI:17574 | ||
Drug Bank ID | DB15334 | ||
KEGG ID | C00814 | ||
Toxicity | Organism | Test Type | Route(Dose) |
rat | LD50 | intraperitoneal(165 mg/kg) | |
mouse | LD50 | intraperitoneal(254 mg/kg) | |
rat | LD50 | oral(322 mg/kg) | |
Structure |
Download
2D
MOL
3D
MOL
|
Chineses Pinyin | HongCheYouCao | ||
Use Part | Flower and inflorescence | ||
Habitat | China | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Fabales
-->Family: Fabaceae
-->Genus: Trifolium
-->Species: Trifolium pratense
|
Pair Name | Biochanin A, Fluorouracil | |||
Partner Name | Fluorouracil | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
Down-regulation | Expression | BIRC5 | hsa332 | |
Down-regulation | Expression | CCND1 | hsa595 | |
Down-regulation | Expression | ESR1 | hsa2099 | |
Down-regulation | Expression | MMP2 | hsa4313 | |
Down-regulation | Expression | VEGFA | hsa7422 | |
In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
In Vivo Model | Ehrlich solid-phase carcinoma was inducedviathe subcutane-ous inoculation of 0.2 ml of ascetic fluid, containing 2.5×10⁶ EACcells, into the right thigh of the hind limb of each mouse. | |||
Result | The synergistic antitumor effect of Bio-A/ 5-FU combination can be, at least partly, attributed to Bio-A-mediated suppression of ER-α/Akt axis and the augmentation of 5-FU-mediated proapoptotic effects. |
Pair Name | Biochanin A, Temozolomide | |||
Partner Name | Temozolomide | |||
Disease Info | [ICD-11: 2A00] | Glioblastoma multiforme | Investigative | |
Biological Phenomena | Induction-->Glycolytic to oxidative phosphorylation | |||
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Down-regulation | Expression | EGFR | hsa1956 | |
Down-regulation | Phosphorylation | MAPK3 | hsa5595 | |
Down-regulation | Expression | MYC | hsa4609 | |
Up-regulation | Phosphorylation | TP53 | hsa7157 | |
In Vitro Model | U-87MG ATCC | Glioblastoma | Homo sapiens (Human) | CVCL_0022 |
T98G | Glioblastoma | Homo sapiens (Human) | CVCL_0556 | |
Result | Chanin A significantly enhanced the anticancer efficacy of temozolomide in GBM cells. |
Pair Name | Biochanin A, SB590885 | |||
Partner Name | SB590885 | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Down-regulation | Expression | CCND1 | hsa595 | |
Up-regulation | Expression | CDKN1A | hsa1026 | |
Down-regulation | Phosphorylation | MAP2K7 | hsa5609 | |
Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | PSMD9 | hsa5715 | |
Down-regulation | Phosphorylation | RPS6 | hsa6194 | |
Down-regulation | Phosphorylation | RPS6KB1 | hsa6198 | |
In Vitro Model | BEL-7402 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_5492 |
SK-HEP-1 | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens (Human) | CVCL_0525 | |
In Vivo Model | 5×10⁶ Bel-7402 cells were injected subcutaneously into the right flank near the hind leg of each nude mouse until the tumor volume was ~ 100 mm3. | |||
Result | The results identify an effective combination therapy for the most aggressive form of HCC and provide the possibility of therapeutic improvement for patients with advanced HCC. |
No. | Title | Href |
---|---|---|
1 | The combination of Biochanin A and SB590885 potentiates the inhibition of tumour progression in hepatocellular carcinoma. Cancer Cell Int. 2020 Aug 5;20:371. doi: 10.1186/s12935-020-01463-w. | Click |
2 | The natural isoflavone Biochanin-A synergizes 5-fluorouracil anticancer activity in vitro and in vivo in Ehrlich solid-phase carcinoma model. Phytother Res. 2022 Mar;36(3):1310-1325. doi: 10.1002/ptr.7388. | Click |
3 | Combination of Biochanin A and Temozolomide Impairs Tumor Growth by Modulating Cell Metabolism in Glioblastoma Multiforme. Anticancer Res. 2019 Jan;39(1):57-66. doi: 10.21873/anticanres.13079. | Click |